Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/30095
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Çalışkan, Yaşar | - |
dc.contributor.author | Torun, Ege Sinan | - |
dc.contributor.author | Tiryaki, Tarık Onur | - |
dc.contributor.author | Özlük, Yasemin | - |
dc.contributor.author | Akgül, Sebahat Usta | - |
dc.contributor.author | Temürhan, Sonay | - |
dc.contributor.author | Öztop, Nida | - |
dc.contributor.author | Kılıçaslan, Işın | - |
dc.contributor.author | Sever, Mehmet Şükrü | - |
dc.date.accessioned | 2022-12-26T12:48:13Z | - |
dc.date.available | 2022-12-26T12:48:13Z | - |
dc.date.issued | 2017-06-17 | - |
dc.identifier.citation | Çalışkan, Y. vd. (2017). ''Immunosuppressive treatment in C3 glomerulopathy: Is it really effective?''. American Journal of Nephrology, 46(2), 96-107. | en_US |
dc.identifier.issn | 0250-8095 | - |
dc.identifier.uri | https://doi.org/10.1159/000479012 | - |
dc.identifier.uri | https://www.karger.com/Article/FullText/479012 | - |
dc.identifier.uri | 1421-9670 | - |
dc.identifier.uri | http://hdl.handle.net/11452/30095 | - |
dc.description.abstract | Background: C3 glomerulopathy (C3GP) is a recently identified and described disease that has a high risk of progressing into end-stage renal disease. We aimed to evaluate the effects of various immunosuppressive regimens on C3GP progression because there are conflicting data on the treatment modalities. Methods: In this retrospective study of 66 patients with C3GP, 27 patients received mycophenolate mofetil (MMF)-based treatment, 23 received non-MMF-based treatment (prednisolone or cyclophosphamide), and 16 received conservative care. The study groups were compared with each other with specific focus on primary outcomes defined as (1) kidney failure and (2) estimated glomerular filtration rate (eGFR) decline >= 50% from the baseline value. Results: Overall, 17 (25.8%) patients reached the primary outcome after a median period of 28 months. The number of patients who reached the primary outcome were similar among the study groups (MMF-based: 8/27 [29.6%], non-MMF-based: 4/23 [17.4%], and conservative care: 5/16 [31.3%], p = 0.520). In the Cox regression analysis, age (HR 0.912, p = 0.006), eGFR (HR 0.945, p = 0.001), and proteinuria levels (HR 1.418, p = 0.015) at the time of biopsy, percentage of crescentic (HR 1.035, p = 0.001) and sclerotic glomeruli (HR 1.041, p = 0.006), severity of interstitial fibrosis (HR 1.981, p = 0.048), as well as no remission of proteinuria (HR 2.418, p = 0.002) predicted the primary outcome. Conclusion: Although patients receiving immunosuppressive treatments had higher proteinuria and lower serum albumin at baseline, there were no differences between these patients and those receiving conservative care alone in proteinuria remission or in the decline of renal function. Younger age, higher proteinuria, lower eGFR, and the presence of crescentic and sclerotic glomeruli, severity of interstitial fibrosis, and no remission of proteinuria predicted the progression of kidney disease. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Karger | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Urology & nephrology | en_US |
dc.subject | C3 glomerulopathy | en_US |
dc.subject | Complement system | en_US |
dc.subject | End-stage renal disease | en_US |
dc.subject | Proteinuria | en_US |
dc.subject | Dense deposit disease | en_US |
dc.subject | Hemolytic-uremic syndrome | en_US |
dc.subject | Complement abnormalities | en_US |
dc.subject | Eculizumab | en_US |
dc.subject | Glomerulonephritis | en_US |
dc.subject | Adult | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Age factors | en_US |
dc.subject.mesh | Anti-Inflammatory agents | en_US |
dc.subject.mesh | Biopsy | en_US |
dc.subject.mesh | Complement C3 | en_US |
dc.subject.mesh | Creatinine | en_US |
dc.subject.mesh | Disease progression | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Fibrosis | en_US |
dc.subject.mesh | Glomerular filtration rate | en_US |
dc.subject.mesh | Glomerulonephritis | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunosuppressive agents | en_US |
dc.subject.mesh | Kidney failure, chronic | en_US |
dc.subject.mesh | Kidney glomerulus | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Proteinuria | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Risk factors | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.mesh | Young adult | en_US |
dc.title | Immunosuppressive treatment in C3 glomerulopathy: Is it really effective? | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000408371900002 | tr_TR |
dc.identifier.scopus | 2-s2.0-85023751797 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Nefroloji Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 96 | tr_TR |
dc.identifier.endpage | 107 | tr_TR |
dc.identifier.volume | 46 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.relation.journal | American Journal of Nephrology | en_US |
dc.contributor.buuauthor | Oruç, Ayşegül | - |
dc.contributor.researcherid | AAH-4002-2021 | tr_TR |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.identifier.pubmed | 28700996 | tr_TR |
dc.subject.wos | Urology & nephrology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q2 | en_US |
dc.contributor.scopusid | 55133912100 | tr_TR |
dc.subject.scopus | Immunoglobulin A Nephropathy; Proteinuria; Kidney Diseases | en_US |
dc.subject.emtree | Albumin | en_US |
dc.subject.emtree | Complement component C1q | en_US |
dc.subject.emtree | Complement component C3 | en_US |
dc.subject.emtree | Cyclophosphamide | en_US |
dc.subject.emtree | Immunoglobulin A | en_US |
dc.subject.emtree | Immunoglobulin G | en_US |
dc.subject.emtree | Immunoglobulin M | en_US |
dc.subject.emtree | Mycophenolate mofetil | en_US |
dc.subject.emtree | Prednisolone | en_US |
dc.subject.emtree | Antiinflammatory agent | en_US |
dc.subject.emtree | C3 protein, human | en_US |
dc.subject.emtree | Complement component C3 | en_US |
dc.subject.emtree | Creatinine | en_US |
dc.subject.emtree | Immunosuppressive agent | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Anemia | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Bladder disease | en_US |
dc.subject.emtree | Blood cell count | en_US |
dc.subject.emtree | Clinical outcome | en_US |
dc.subject.emtree | Conservative treatment | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Creatinine blood level | en_US |
dc.subject.emtree | Diarrhea | en_US |
dc.subject.emtree | Drug dose reduction | en_US |
dc.subject.emtree | Drug megadose | en_US |
dc.subject.emtree | Drug withdrawal | en_US |
dc.subject.emtree | Estimated glomerular filtration rate | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Fibrosing alveolitis | en_US |
dc.subject.emtree | Gender | en_US |
dc.subject.emtree | Glomerulopathy | en_US |
dc.subject.emtree | Hematuria | en_US |
dc.subject.emtree | Histopathology | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Hypocomplementemia | en_US |
dc.subject.emtree | Immunofluorescence | en_US |
dc.subject.emtree | Immunofluorescence test | en_US |
dc.subject.emtree | Immunosuppressive treatment | en_US |
dc.subject.emtree | Kidney biopsy | en_US |
dc.subject.emtree | Kidney failure | en_US |
dc.subject.emtree | Leukopenia | en_US |
dc.subject.emtree | Low drug dose | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Membranoproliferative glomerulonephritis | en_US |
dc.subject.emtree | Nausea | en_US |
dc.subject.emtree | Nephrotic syndrome | en_US |
dc.subject.emtree | Pneumonia | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Proteinuria | en_US |
dc.subject.emtree | Remission | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Sanger sequencin | en_US |
dc.subject.emtree | Thrombocytopenia | en_US |
dc.subject.emtree | Age | en_US |
dc.subject.emtree | Biopsy | en_US |
dc.subject.emtree | Blood | en_US |
dc.subject.emtree | Chronic kidney failure | en_US |
dc.subject.emtree | Comparative study | en_US |
dc.subject.emtree | Disease exacerbation | en_US |
dc.subject.emtree | Fibrosis | en_US |
dc.subject.emtree | Glomerulonephritis | en_US |
dc.subject.emtree | Glomerulus | en_US |
dc.subject.emtree | Glomerulus filtration rate | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Proteinuria | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.emtree | Urine | en_US |
dc.subject.emtree | Young adult | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.